Alembic enters into licensing pact with Belgian co
24 May 2007
Mumbai: Drug maker Alembic has signed a licensing
agreement with Belgian drugmaker UCB, a global biopharmaceutical
company, engaged in R&D and commercialisation of pharmaceutical
and biotechnology products in the fields of central nervous
system disorders, for its Novel Drug Delivery Platform
for epilepsy drug Keppra XR (Levetiracetam extended release
tablets).
As per the agreement, Alembic will provide the technology to reduce the dosage for the twice-a-day Keppra drug to make it a once-a-day tablet. The tablet will then be sold in dosages of 500 mg, 1000 mg and 1500 mg and will be called Keppra XR.
Alembic would receive milestone payments of $11 million and additionally get royalty payments on future worldwide net sales of the Keppra drug, subject to necessary legal and regulatory approvals. Phase III clinical trials on Keppra XR (Levetiracetam Extended Release tablets) are ongoing and results are expected in the fourth quarter of 2007, the company said.
Keppra is UCB''s leading anti-epileptic drug, with sales of 761 million ($1 billion) in 2006.
In
2006 UCB had a turnover of $2.5 billion.
Latest articles
.webp)
Featured articles
The New Airspace Economy: How Geopolitics Is Rewriting Aviation Costs in 2026
By Axel Miller | 22 Jan 2026
Airspace bans, sanctions and corridor risk are forcing airlines into costly detours in 2026, raising fuel burn, reducing aircraft utilisation and pushing airfares higher worldwide.
India’s Data Center Arms Race: The Battle for Power, Cooling, and AI Real Estate
By Cygnus | 22 Jan 2026
India’s data centre boom is turning into an AI arms race where power contracts, liquid cooling and fast commissioning decide the winners across Mumbai, Chennai and Hyderabad.
India’s Oil Balancing Act: Refiners Rebuild Middle East Supply Lines as Russia Flows Disrupt
By Axel Miller | 21 Jan 2026
India’s refiners are rebalancing crude sourcing as Russian imports fell to a two-year low in December 2025, lifting OPEC’s share and raising geopolitical risk concerns.
Arctic Fever: How ‘Greenland Tariff’ Politics Sparked a Global Flight to Safety
By Axel Miller | 20 Jan 2026
Greenland-linked tariff threats have injected fresh uncertainty into transatlantic trade, triggering a risk-off shift in markets and reshaping global supply chain planning.
The New Oil (Part 5): Friend-Shoring, Supply Chain Fragmentation and the Cost of Resilience
By Cygnus | 19 Jan 2026
Friend-shoring is reshaping lithium, rare earth and graphite supply chains, creating a resilience premium and new winners and losers in clean tech.
The New Oil (Part 4): Can Technology Break the Dependency?
By Cygnus | 16 Jan 2026
Can magnet recycling and rare-earth-free motors reduce global dependence on strategic minerals? Part 4 explores breakthroughs, limits and timelines.
India’s Gig Economy Reset: The End of ‘10-Minute Delivery’ Hype?
By Cygnus | 14 Jan 2026
India’s quick-commerce sector is shifting away from “10-minute delivery” hype amid worker safety concerns and rising regulation. Here’s what changes—and what doesn’t.
AI Is Becoming the New Electricity Crisis: Why the Real Bottleneck Is Megawatts
By Axel Miller | 14 Jan 2026
AI is turning into an electricity crisis as data centres scale from chips to megawatts. Grid bottlenecks, copper demand and cooling limits are now the real AI constraints.
The New Oil (Part 3): Can Technology End the Rare Earth Dependency?
By Cygnus | 14 Jan 2026
Magnet recycling and rare-earth-free motors are emerging as technology escape routes from critical mineral dependency. But timelines are slower than the hype suggests.
